Barclays
IRD

Barclays’s Opus Genetics IRD Stock Holding History

Barclays’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.64K Hold
1,900
– – ﹤0.01% 4718
2025
Q4 		$3.82K Hold
1,900
– – ﹤0.01% 5006
2025
Q3 		$3.13K Hold
1,900
– – ﹤0.01% 5123
2025
Q2 		$1.79K Hold
1,900
– – ﹤0.01% 5043
2025
Q1 		$1.86K Buy
+1,900
New +$2.12K ﹤0.01% 4999
2024
Q4 		– Sell
-1,900
Closed -$2.49K – 5535
2024
Q3 		$2.49K Buy
+1,900
New +$2.92K ﹤0.01% 5069

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Barclays's IRD Position: Q1 2026 in Review

Barclays held its Opus Genetics (IRD) position steady in Q1 2026 at 1,900 shares worth $8.64K. The position accounts for ﹤0.01% of the portfolio, ranked #4718.

Barclays first reported a position in IRD in Q3 2024 and has held it in 6 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Barclays held 1,900 shares of Opus Genetics worth $8.64K as of Q1 2026.
  • Barclays left its Opus Genetics share count unchanged in Q1 2026.
  • Opus Genetics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4718 holding.
  • Barclays first reported a position in Opus Genetics in Q3 2024 and has held it in 6 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.